Liver Fibrosis by Transient Elastography and Virologic Outcomes After Introduction of Tenofovir in Lamivudine-Experienced Adults With HIV and Hepatitis B Virus Coinfection in Ghana.
Identifieur interne : 000211 ( PubMed/Checkpoint ); précédent : 000210; suivant : 000212Liver Fibrosis by Transient Elastography and Virologic Outcomes After Introduction of Tenofovir in Lamivudine-Experienced Adults With HIV and Hepatitis B Virus Coinfection in Ghana.
Auteurs : Alexander J. Stockdale [Royaume-Uni] ; Richard Odame Phillips [Ghana] ; Apostolos Beloukas [Royaume-Uni] ; Lambert Tetteh Appiah [Ghana] ; David Chadwick ; Sanjay Bhagani [Royaume-Uni] ; Laura Bonnett ; Fred Stephen Sarfo [Ghana] ; Geoffrey Dusheiko [Royaume-Uni] ; Anna Maria Geretti [Royaume-Uni]Source :
- Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [ 1537-6591 ] ; 2015.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Afrique subsaharienne, Antiviraux (usage thérapeutique), Charge virale, Cirrhose du foie (diagnostic), Cirrhose du foie (épidémiologie), Co-infection (traitement médicamenteux), Femelle, Ghana, Humains, Hépatite B chronique (), Hépatite B chronique (traitement médicamenteux), Hépatite B chronique (virologie), Imagerie d'élasticité tissulaire, Infections à VIH (), Lamivudine (usage thérapeutique), Mâle, Résultat thérapeutique, Ténofovir (usage thérapeutique), VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (), VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (génétique), VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (isolement et purification), Virus de l'hépatite B (génétique), Virus de l'hépatite B (isolement et purification), Études prospectives, Études transversales.
- MESH :
- diagnostic : Cirrhose du foie.
- génétique : VIH-1 (Virus de l'Immunodéficience Humaine de type 1), Virus de l'hépatite B.
- isolement et purification : VIH-1 (Virus de l'Immunodéficience Humaine de type 1), Virus de l'hépatite B.
- traitement médicamenteux : Co-infection, Hépatite B chronique.
- usage thérapeutique : Antiviraux, Lamivudine, Ténofovir.
- virologie : Hépatite B chronique.
- épidémiologie : Cirrhose du foie.
- Adulte, Adulte d'âge moyen, Afrique subsaharienne, Charge virale, Femelle, Ghana, Humains, Hépatite B chronique, Imagerie d'élasticité tissulaire, Infections à VIH, Mâle, Résultat thérapeutique, VIH-1 (Virus de l'Immunodéficience Humaine de type 1), Études prospectives, Études transversales.
- Wicri :
- geographic : Ghana.
English descriptors
- KwdEn :
- Adult, Africa South of the Sahara, Antiviral Agents (therapeutic use), Coinfection (drug therapy), Cross-Sectional Studies, Elasticity Imaging Techniques, Female, Ghana, HIV Infections (complications), HIV-1 (classification), HIV-1 (genetics), HIV-1 (isolation & purification), Hepatitis B virus (genetics), Hepatitis B virus (isolation & purification), Hepatitis B, Chronic (complications), Hepatitis B, Chronic (drug therapy), Hepatitis B, Chronic (virology), Humans, Lamivudine (therapeutic use), Liver Cirrhosis (diagnosis), Liver Cirrhosis (epidemiology), Male, Middle Aged, Prospective Studies, Tenofovir (therapeutic use), Treatment Outcome, Viral Load.
- MESH :
- chemical , therapeutic use : Antiviral Agents, Lamivudine, Tenofovir.
- geographic : Africa South of the Sahara, Ghana.
- classification : HIV-1.
- complications : HIV Infections, Hepatitis B, Chronic.
- diagnosis : Liver Cirrhosis.
- drug therapy : Coinfection, Hepatitis B, Chronic.
- epidemiology : Liver Cirrhosis.
- genetics : HIV-1, Hepatitis B virus.
- isolation & purification : HIV-1, Hepatitis B virus.
- virology : Hepatitis B, Chronic.
- Adult, Cross-Sectional Studies, Elasticity Imaging Techniques, Female, Humans, Male, Middle Aged, Prospective Studies, Treatment Outcome, Viral Load.
Abstract
Antiretroviral treatment (ART) programs in sub-Saharan Africa have for many years included lamivudine as the sole hepatitis B virus (HBV) inhibitor. Long-term outcomes and the effects of introducing tenofovir as part of ART in these populations have not been characterized.
DOI: 10.1093/cid/civ421
PubMed: 26021992
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:26021992Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Liver Fibrosis by Transient Elastography and Virologic Outcomes After Introduction of Tenofovir in Lamivudine-Experienced Adults With HIV and Hepatitis B Virus Coinfection in Ghana.</title><author><name sortKey="Stockdale, Alexander J" sort="Stockdale, Alexander J" uniqKey="Stockdale A" first="Alexander J" last="Stockdale">Alexander J. Stockdale</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Infection and Global Health, University of Liverpool, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Institute of Infection and Global Health, University of Liverpool</wicri:regionArea><wicri:noRegion>University of Liverpool</wicri:noRegion></affiliation></author><author><name sortKey="Phillips, Richard Odame" sort="Phillips, Richard Odame" uniqKey="Phillips R" first="Richard Odame" last="Phillips">Richard Odame Phillips</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Kwame Nkrumah University of Science and Technology Komfo Anokye Teaching Hospital, Kumasi, Ghana.</nlm:affiliation><country xml:lang="fr">Ghana</country><wicri:regionArea>Department of Medicine, Kwame Nkrumah University of Science and Technology Komfo Anokye Teaching Hospital, Kumasi</wicri:regionArea><wicri:noRegion>Kumasi</wicri:noRegion></affiliation></author><author><name sortKey="Beloukas, Apostolos" sort="Beloukas, Apostolos" uniqKey="Beloukas A" first="Apostolos" last="Beloukas">Apostolos Beloukas</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Infection and Global Health, University of Liverpool, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Institute of Infection and Global Health, University of Liverpool</wicri:regionArea><wicri:noRegion>University of Liverpool</wicri:noRegion></affiliation></author><author><name sortKey="Appiah, Lambert Tetteh" sort="Appiah, Lambert Tetteh" uniqKey="Appiah L" first="Lambert Tetteh" last="Appiah">Lambert Tetteh Appiah</name><affiliation wicri:level="1"><nlm:affiliation>Komfo Anokye Teaching Hospital, Kumasi, Ghana.</nlm:affiliation><country xml:lang="fr">Ghana</country><wicri:regionArea>Komfo Anokye Teaching Hospital, Kumasi</wicri:regionArea><wicri:noRegion>Kumasi</wicri:noRegion></affiliation></author><author><name sortKey="Chadwick, David" sort="Chadwick, David" uniqKey="Chadwick D" first="David" last="Chadwick">David Chadwick</name><affiliation><nlm:affiliation>Centre for Clinical Infection, James Cook University Hospital, Middlesbrough.</nlm:affiliation><wicri:noCountry code="subField">Middlesbrough</wicri:noCountry></affiliation></author><author><name sortKey="Bhagani, Sanjay" sort="Bhagani, Sanjay" uniqKey="Bhagani S" first="Sanjay" last="Bhagani">Sanjay Bhagani</name><affiliation wicri:level="3"><nlm:affiliation>Department of Infectious Diseases, Royal Free Hospital, London.</nlm:affiliation><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName><wicri:orgArea>Department of Infectious Diseases, Royal Free Hospital</wicri:orgArea></affiliation></author><author><name sortKey="Bonnett, Laura" sort="Bonnett, Laura" uniqKey="Bonnett L" first="Laura" last="Bonnett">Laura Bonnett</name><affiliation><nlm:affiliation>Institute of Infection and Global Health, University of Liverpool, United Kingdom Department of Biostatistics, University of Liverpool.</nlm:affiliation><wicri:noCountry code="subField">University of Liverpool</wicri:noCountry></affiliation></author><author><name sortKey="Sarfo, Fred Stephen" sort="Sarfo, Fred Stephen" uniqKey="Sarfo F" first="Fred Stephen" last="Sarfo">Fred Stephen Sarfo</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Kwame Nkrumah University of Science and Technology Komfo Anokye Teaching Hospital, Kumasi, Ghana.</nlm:affiliation><country xml:lang="fr">Ghana</country><wicri:regionArea>Department of Medicine, Kwame Nkrumah University of Science and Technology Komfo Anokye Teaching Hospital, Kumasi</wicri:regionArea><wicri:noRegion>Kumasi</wicri:noRegion></affiliation></author><author><name sortKey="Dusheiko, Geoffrey" sort="Dusheiko, Geoffrey" uniqKey="Dusheiko G" first="Geoffrey" last="Dusheiko">Geoffrey Dusheiko</name><affiliation wicri:level="4"><nlm:affiliation>Division of Medicine, University College London, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Division of Medicine, University College London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName><orgName type="university">University College de Londres</orgName></affiliation></author><author><name sortKey="Geretti, Anna Maria" sort="Geretti, Anna Maria" uniqKey="Geretti A" first="Anna Maria" last="Geretti">Anna Maria Geretti</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Infection and Global Health, University of Liverpool, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Institute of Infection and Global Health, University of Liverpool</wicri:regionArea><wicri:noRegion>University of Liverpool</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:26021992</idno><idno type="pmid">26021992</idno><idno type="doi">10.1093/cid/civ421</idno><idno type="wicri:Area/PubMed/Corpus">000083</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000083</idno><idno type="wicri:Area/PubMed/Curation">000083</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000083</idno><idno type="wicri:Area/PubMed/Checkpoint">000083</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000083</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Liver Fibrosis by Transient Elastography and Virologic Outcomes After Introduction of Tenofovir in Lamivudine-Experienced Adults With HIV and Hepatitis B Virus Coinfection in Ghana.</title><author><name sortKey="Stockdale, Alexander J" sort="Stockdale, Alexander J" uniqKey="Stockdale A" first="Alexander J" last="Stockdale">Alexander J. Stockdale</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Infection and Global Health, University of Liverpool, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Institute of Infection and Global Health, University of Liverpool</wicri:regionArea><wicri:noRegion>University of Liverpool</wicri:noRegion></affiliation></author><author><name sortKey="Phillips, Richard Odame" sort="Phillips, Richard Odame" uniqKey="Phillips R" first="Richard Odame" last="Phillips">Richard Odame Phillips</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Kwame Nkrumah University of Science and Technology Komfo Anokye Teaching Hospital, Kumasi, Ghana.</nlm:affiliation><country xml:lang="fr">Ghana</country><wicri:regionArea>Department of Medicine, Kwame Nkrumah University of Science and Technology Komfo Anokye Teaching Hospital, Kumasi</wicri:regionArea><wicri:noRegion>Kumasi</wicri:noRegion></affiliation></author><author><name sortKey="Beloukas, Apostolos" sort="Beloukas, Apostolos" uniqKey="Beloukas A" first="Apostolos" last="Beloukas">Apostolos Beloukas</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Infection and Global Health, University of Liverpool, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Institute of Infection and Global Health, University of Liverpool</wicri:regionArea><wicri:noRegion>University of Liverpool</wicri:noRegion></affiliation></author><author><name sortKey="Appiah, Lambert Tetteh" sort="Appiah, Lambert Tetteh" uniqKey="Appiah L" first="Lambert Tetteh" last="Appiah">Lambert Tetteh Appiah</name><affiliation wicri:level="1"><nlm:affiliation>Komfo Anokye Teaching Hospital, Kumasi, Ghana.</nlm:affiliation><country xml:lang="fr">Ghana</country><wicri:regionArea>Komfo Anokye Teaching Hospital, Kumasi</wicri:regionArea><wicri:noRegion>Kumasi</wicri:noRegion></affiliation></author><author><name sortKey="Chadwick, David" sort="Chadwick, David" uniqKey="Chadwick D" first="David" last="Chadwick">David Chadwick</name><affiliation><nlm:affiliation>Centre for Clinical Infection, James Cook University Hospital, Middlesbrough.</nlm:affiliation><wicri:noCountry code="subField">Middlesbrough</wicri:noCountry></affiliation></author><author><name sortKey="Bhagani, Sanjay" sort="Bhagani, Sanjay" uniqKey="Bhagani S" first="Sanjay" last="Bhagani">Sanjay Bhagani</name><affiliation wicri:level="3"><nlm:affiliation>Department of Infectious Diseases, Royal Free Hospital, London.</nlm:affiliation><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName><wicri:orgArea>Department of Infectious Diseases, Royal Free Hospital</wicri:orgArea></affiliation></author><author><name sortKey="Bonnett, Laura" sort="Bonnett, Laura" uniqKey="Bonnett L" first="Laura" last="Bonnett">Laura Bonnett</name><affiliation><nlm:affiliation>Institute of Infection and Global Health, University of Liverpool, United Kingdom Department of Biostatistics, University of Liverpool.</nlm:affiliation><wicri:noCountry code="subField">University of Liverpool</wicri:noCountry></affiliation></author><author><name sortKey="Sarfo, Fred Stephen" sort="Sarfo, Fred Stephen" uniqKey="Sarfo F" first="Fred Stephen" last="Sarfo">Fred Stephen Sarfo</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Kwame Nkrumah University of Science and Technology Komfo Anokye Teaching Hospital, Kumasi, Ghana.</nlm:affiliation><country xml:lang="fr">Ghana</country><wicri:regionArea>Department of Medicine, Kwame Nkrumah University of Science and Technology Komfo Anokye Teaching Hospital, Kumasi</wicri:regionArea><wicri:noRegion>Kumasi</wicri:noRegion></affiliation></author><author><name sortKey="Dusheiko, Geoffrey" sort="Dusheiko, Geoffrey" uniqKey="Dusheiko G" first="Geoffrey" last="Dusheiko">Geoffrey Dusheiko</name><affiliation wicri:level="4"><nlm:affiliation>Division of Medicine, University College London, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Division of Medicine, University College London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName><orgName type="university">University College de Londres</orgName></affiliation></author><author><name sortKey="Geretti, Anna Maria" sort="Geretti, Anna Maria" uniqKey="Geretti A" first="Anna Maria" last="Geretti">Anna Maria Geretti</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Infection and Global Health, University of Liverpool, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Institute of Infection and Global Health, University of Liverpool</wicri:regionArea><wicri:noRegion>University of Liverpool</wicri:noRegion></affiliation></author></analytic><series><title level="j">Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</title><idno type="eISSN">1537-6591</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Africa South of the Sahara</term><term>Antiviral Agents (therapeutic use)</term><term>Coinfection (drug therapy)</term><term>Cross-Sectional Studies</term><term>Elasticity Imaging Techniques</term><term>Female</term><term>Ghana</term><term>HIV Infections (complications)</term><term>HIV-1 (classification)</term><term>HIV-1 (genetics)</term><term>HIV-1 (isolation & purification)</term><term>Hepatitis B virus (genetics)</term><term>Hepatitis B virus (isolation & purification)</term><term>Hepatitis B, Chronic (complications)</term><term>Hepatitis B, Chronic (drug therapy)</term><term>Hepatitis B, Chronic (virology)</term><term>Humans</term><term>Lamivudine (therapeutic use)</term><term>Liver Cirrhosis (diagnosis)</term><term>Liver Cirrhosis (epidemiology)</term><term>Male</term><term>Middle Aged</term><term>Prospective Studies</term><term>Tenofovir (therapeutic use)</term><term>Treatment Outcome</term><term>Viral Load</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Afrique subsaharienne</term><term>Antiviraux (usage thérapeutique)</term><term>Charge virale</term><term>Cirrhose du foie (diagnostic)</term><term>Cirrhose du foie (épidémiologie)</term><term>Co-infection (traitement médicamenteux)</term><term>Femelle</term><term>Ghana</term><term>Humains</term><term>Hépatite B chronique ()</term><term>Hépatite B chronique (traitement médicamenteux)</term><term>Hépatite B chronique (virologie)</term><term>Imagerie d'élasticité tissulaire</term><term>Infections à VIH ()</term><term>Lamivudine (usage thérapeutique)</term><term>Mâle</term><term>Résultat thérapeutique</term><term>Ténofovir (usage thérapeutique)</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1) ()</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (génétique)</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (isolement et purification)</term><term>Virus de l'hépatite B (génétique)</term><term>Virus de l'hépatite B (isolement et purification)</term><term>Études prospectives</term><term>Études transversales</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Lamivudine</term><term>Tenofovir</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Africa South of the Sahara</term><term>Ghana</term></keywords><keywords scheme="MESH" qualifier="classification" xml:lang="en"><term>HIV-1</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>HIV Infections</term><term>Hepatitis B, Chronic</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Liver Cirrhosis</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Cirrhose du foie</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coinfection</term><term>Hepatitis B, Chronic</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Liver Cirrhosis</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>HIV-1</term><term>Hepatitis B virus</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term><term>Virus de l'hépatite B</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>HIV-1</term><term>Hepatitis B virus</term></keywords><keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term><term>Virus de l'hépatite B</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Co-infection</term><term>Hépatite B chronique</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term><term>Lamivudine</term><term>Ténofovir</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Hépatite B chronique</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Hepatitis B, Chronic</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Cirrhose du foie</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Cross-Sectional Studies</term><term>Elasticity Imaging Techniques</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Prospective Studies</term><term>Treatment Outcome</term><term>Viral Load</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Afrique subsaharienne</term><term>Charge virale</term><term>Femelle</term><term>Ghana</term><term>Humains</term><term>Hépatite B chronique</term><term>Imagerie d'élasticité tissulaire</term><term>Infections à VIH</term><term>Mâle</term><term>Résultat thérapeutique</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term><term>Études prospectives</term><term>Études transversales</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Ghana</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Antiretroviral treatment (ART) programs in sub-Saharan Africa have for many years included lamivudine as the sole hepatitis B virus (HBV) inhibitor. Long-term outcomes and the effects of introducing tenofovir as part of ART in these populations have not been characterized.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26021992</PMID><DateCreated><Year>2015</Year><Month>08</Month><Day>28</Day></DateCreated><DateCompleted><Year>2016</Year><Month>06</Month><Day>06</Day></DateCompleted><DateRevised><Year>2015</Year><Month>08</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1537-6591</ISSN><JournalIssue CitedMedium="Internet"><Volume>61</Volume><Issue>6</Issue><PubDate><Year>2015</Year><Month>Sep</Month><Day>15</Day></PubDate></JournalIssue><Title>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</Title><ISOAbbreviation>Clin. Infect. Dis.</ISOAbbreviation></Journal><ArticleTitle>Liver Fibrosis by Transient Elastography and Virologic Outcomes After Introduction of Tenofovir in Lamivudine-Experienced Adults With HIV and Hepatitis B Virus Coinfection in Ghana.</ArticleTitle><Pagination><MedlinePgn>883-91</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/cid/civ421</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Antiretroviral treatment (ART) programs in sub-Saharan Africa have for many years included lamivudine as the sole hepatitis B virus (HBV) inhibitor. Long-term outcomes and the effects of introducing tenofovir as part of ART in these populations have not been characterized.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The study comprised a cross-sectional analysis of 106 human immunodeficiency virus (HIV)/HBV-coinfected subjects maintained on lamivudine, as well as a prospective analysis of 76 lamivudine-experienced subjects who introduced tenofovir. Patients underwent assessment of liver fibrosis by transient elastography (TE) and testing to characterize HIV type 1 (HIV-1) and HBV replication.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">After a median of 45 months of lamivudine treatment, HIV-1 RNA and HBV DNA were detectable in 35 of 106 (33.0%) and 54 of 106 (50.9%) subjects, respectively, with corresponding drug resistance rates of 17 of 106 (16.0%) and 31 of 106 (29.2%), respectively. Median TE values were 5.7 kPa (interquartile range, 4.7-7.2 kPa) and independently associated with HBV DNA load, aspartate aminotransferase levels, and platelet counts; 13 of 106 (12.3%) subjects had TE measurements >9.4 kPa. Twelve months after the first assessment, and a median of 7.8 months after introducing tenofovir, HBV DNA levels declined by a mean of 1.5 log10 IU/mL (P < .001). TE values changed by a mean of -0.2 kPa (P = .097), and declined significantly in subjects who had pretenofovir HBV DNA levels >2000 IU/mL (mean, -0.8 kPa; P = .048) or TE values >7.6 kPa (mean, -1.2 kPa; P = .021). HIV-1 RNA detection rates remained unchanged.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">A proportion of HIV/HBV-coinfected patients on long-term lamivudine-containing ART had poor HIV and HBV suppression, drug resistance, and TE values indicative of advanced liver fibrosis. Tenofovir improved HBV control and reduced liver stiffness in subjects with high HBV DNA load and TE values.</AbstractText><CopyrightInformation>© The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stockdale</LastName><ForeName>Alexander J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Institute of Infection and Global Health, University of Liverpool, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Phillips</LastName><ForeName>Richard Odame</ForeName><Initials>RO</Initials><AffiliationInfo><Affiliation>Department of Medicine, Kwame Nkrumah University of Science and Technology Komfo Anokye Teaching Hospital, Kumasi, Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beloukas</LastName><ForeName>Apostolos</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Infection and Global Health, University of Liverpool, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Appiah</LastName><ForeName>Lambert Tetteh</ForeName><Initials>LT</Initials><AffiliationInfo><Affiliation>Komfo Anokye Teaching Hospital, Kumasi, Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chadwick</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Centre for Clinical Infection, James Cook University Hospital, Middlesbrough.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhagani</LastName><ForeName>Sanjay</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Royal Free Hospital, London.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonnett</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute of Infection and Global Health, University of Liverpool, United Kingdom Department of Biostatistics, University of Liverpool.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarfo</LastName><ForeName>Fred Stephen</ForeName><Initials>FS</Initials><AffiliationInfo><Affiliation>Department of Medicine, Kwame Nkrumah University of Science and Technology Komfo Anokye Teaching Hospital, Kumasi, Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dusheiko</LastName><ForeName>Geoffrey</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Medicine, University College London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geretti</LastName><ForeName>Anna Maria</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Institute of Infection and Global Health, University of Liverpool, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Hepatitis B Infection in Kumasi (HEPIK) Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>05</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Infect Dis</MedlineTA><NlmUniqueID>9203213</NlmUniqueID><ISSNLinking>1058-4838</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>2T8Q726O95</RegistryNumber><NameOfSubstance UI="D019259">Lamivudine</NameOfSubstance></Chemical><Chemical><RegistryNumber>99YXE507IL</RegistryNumber><NameOfSubstance UI="D000068698">Tenofovir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Clin Infect Dis. 2016 Jan 1;62(1):128-30</RefSource><PMID Version="1">26338780</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Clin Infect Dis. 2016 Jan 1;62(1):130-1</RefSource><PMID Version="1">26338792</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017954" MajorTopicYN="N" Type="Geographic">Africa South of the Sahara</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060085" MajorTopicYN="N">Coinfection</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054459" MajorTopicYN="N">Elasticity Imaging Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005869" MajorTopicYN="N" Type="Geographic">Ghana</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015497" MajorTopicYN="N">HIV-1</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006515" MajorTopicYN="N">Hepatitis B virus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019694" MajorTopicYN="N">Hepatitis B, Chronic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019259" MajorTopicYN="N">Lamivudine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008103" MajorTopicYN="N">Liver Cirrhosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068698" MajorTopicYN="N">Tenofovir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Africa</Keyword><Keyword MajorTopicYN="N">hepatitis B</Keyword><Keyword MajorTopicYN="N">lamivudine</Keyword><Keyword MajorTopicYN="N">tenofovir</Keyword><Keyword MajorTopicYN="N">transient elastography</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>03</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>05</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>5</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>5</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26021992</ArticleId><ArticleId IdType="pii">civ421</ArticleId><ArticleId IdType="doi">10.1093/cid/civ421</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Ghana</li><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Grand Londres</li></region><settlement><li>Londres</li></settlement><orgName><li>University College de Londres</li></orgName></list><tree><noCountry><name sortKey="Bonnett, Laura" sort="Bonnett, Laura" uniqKey="Bonnett L" first="Laura" last="Bonnett">Laura Bonnett</name><name sortKey="Chadwick, David" sort="Chadwick, David" uniqKey="Chadwick D" first="David" last="Chadwick">David Chadwick</name></noCountry><country name="Royaume-Uni"><noRegion><name sortKey="Stockdale, Alexander J" sort="Stockdale, Alexander J" uniqKey="Stockdale A" first="Alexander J" last="Stockdale">Alexander J. Stockdale</name></noRegion><name sortKey="Beloukas, Apostolos" sort="Beloukas, Apostolos" uniqKey="Beloukas A" first="Apostolos" last="Beloukas">Apostolos Beloukas</name><name sortKey="Bhagani, Sanjay" sort="Bhagani, Sanjay" uniqKey="Bhagani S" first="Sanjay" last="Bhagani">Sanjay Bhagani</name><name sortKey="Dusheiko, Geoffrey" sort="Dusheiko, Geoffrey" uniqKey="Dusheiko G" first="Geoffrey" last="Dusheiko">Geoffrey Dusheiko</name><name sortKey="Geretti, Anna Maria" sort="Geretti, Anna Maria" uniqKey="Geretti A" first="Anna Maria" last="Geretti">Anna Maria Geretti</name></country><country name="Ghana"><noRegion><name sortKey="Phillips, Richard Odame" sort="Phillips, Richard Odame" uniqKey="Phillips R" first="Richard Odame" last="Phillips">Richard Odame Phillips</name></noRegion><name sortKey="Appiah, Lambert Tetteh" sort="Appiah, Lambert Tetteh" uniqKey="Appiah L" first="Lambert Tetteh" last="Appiah">Lambert Tetteh Appiah</name><name sortKey="Sarfo, Fred Stephen" sort="Sarfo, Fred Stephen" uniqKey="Sarfo F" first="Fred Stephen" last="Sarfo">Fred Stephen Sarfo</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000211 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000211 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaGhanaV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:26021992
|texte= Liver Fibrosis by Transient Elastography and Virologic Outcomes After Introduction of Tenofovir in Lamivudine-Experienced Adults With HIV and Hepatitis B Virus Coinfection in Ghana.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:26021992" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a SidaGhanaV1
| This area was generated with Dilib version V0.6.31. |  |